Use of kCNQ-openers for treating or reducing the symptoms of schizophrenia

The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relate...

Full description

Saved in:
Bibliographic Details
Main Authors WATSON WILLIAM PATRICK, ROTTLAENDER MARIO, KHANZHIN NIKOLAY, WENZEL TORNOEE CHRISTIAN, GREVE DANIEL RODRIGUEZ, RITZEN ANDREAS
Format Patent
LanguageChinese
English
Published 04.03.2009
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:The invention relates to a novel method for treating or reducing the symptoms of schizophrenia, said method comprising administering to a host in need thereof an effective amount of a compound able to selectively increase the ion flow through KCNQ potassium channels. Furthermore the invention relates to the use of selective KCNQ potassium channel openers for the preparation of a pharmaceutical composition for treating or reducing the symtoms of schizophrenia and related symptoms, disorders and diseases. Furthermore the invention relates to a method of screening for a compound, which is a selective KCNQ potassium channel opener and which is capable of having an anti-psychotic potential.
Bibliography:Application Number: CN200780004648